The Biologic Importance of Tumor-Infiltrating Lymphocytes

Por Hodi, F. Stephen, Dranoff, Glenn
Publicado em 2010

Anti-PD1 following Ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

Por Min, Le, Hodi, F. Stephen
Publicado em 2013

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

Por Buchbinder, Elizabeth, Hodi, F. Stephen
Publicado no J Clin Invest (2015)

Targeted therapeutics in melanoma

Por Gajewski, Thomas F., Hodi, F. Stephen.
Publicado em 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Por Luke, Jason J., Hodi, F. Stephen
Publicado em 2013

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

Por Jinushi, Masahisa, Hodi, F. Stephen, Dranoff, Glenn
Publicado em 2006

A primate species with limited major histocompatibility complex class I polymorphism.

Por Watkins, D I, Hodi, F S, Letvin, N L
Publicado em 1988

Mutation-driven drug development in melanoma

Por Flaherty, Keith T., Hodi, F. Stephen, Bastian, Boris C.
Publicado em 2010

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma

Por Wu, Xinqi, Marmarelis, Melina E., Hodi, F. Stephen
Publicado em 2013

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

Por Nishino, Mizuki, Sholl, Lynette M., Hodi, F. Stephen
Publicado no N Engl J Med (2015)

Corticosteroids and immune checkpoint blockade

Por Min, Le, Hodi, F. Stephen, Kaiser, Ursula B.
Publicado no Aging (Albany NY) (2015)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial...

Por Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I.
Publicado no Front Oncol (2015)

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

Por Fecher, Leslie A., Agarwala, Sanjiv S., Hodi, F. Stephen, Weber, Jeffrey S.
Publicado em 2013

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Por Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen
Publicado no Nat Rev Clin Oncol (2017)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Por Nishino, Mizuki, Giobbie-Hurder, Anita, Ramaiya, Nikhil H, Hodi, F Stephen
Publicado no J Immunother Cancer (2014)

Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment

Por Nishino, Mizuki, Tirumani, Sree H., Ramaiya, Nikhil H., Hodi, F. Stephen
Publicado no Eur J Radiol (2015)

Antitumor Granuloma Formation by CD4(+) T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Trea...

Por Luke, Jason J., Lezcano, Cecilia, Hodi, F. Stephen, Murphy, George F.
Publicado no J Clin Oncol (2015)

Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer

Por Harshman, Lauren C., Choueiri, Toni K., Drake, Charles, Hodi, F. Stephen
Publicado no Cancer J (2014)

Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways

Por Wu, Xinqi, Li, Jingjing, Zhu, Meijun, Fletcher, Jonathan A., Hodi, F. Stephen
Publicado em 2012

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Por Nishino, Mizuki, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H, Hodi, F Stephen
Publicado em 2014